Alzheimer's Blood Tests Expand to Latin America and Caribbean
C2N Diagnostics and SouthGenetics partner to bring accessible Alzheimer's biomarker blood testing to 9 underserved LATAM nations.
Summary
C2N Diagnostics and SouthGenetics have partnered to expand Alzheimer's blood-based biomarker testing across Latin America and the Caribbean, starting in nine countries including Mexico, Colombia, and Argentina. The Precivity blood test portfolio detects biological signals in the bloodstream linked to Alzheimer's pathology, offering a less expensive and more accessible alternative to specialized brain imaging. This matters because aging populations across the region face growing dementia burdens while access to specialist diagnostics remains limited. The tests are not standalone diagnostic tools but provide additional clinical information to guide physicians. The expansion reflects a broader shift toward earlier Alzheimer's detection, which is increasingly important as new therapies emerge that work best when initiated early in disease progression.
Detailed Summary
Access to Alzheimer's diagnostics has long lagged behind the science, particularly in lower-resource regions. A new partnership between C2N Diagnostics and SouthGenetics aims to change that by expanding the Precivity blood-testing portfolio across nine Latin American and Caribbean countries: Argentina, Chile, Colombia, the Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela.
The core appeal of blood-based biomarker testing is pragmatic. Rather than requiring costly PET imaging or cerebrospinal fluid analysis, these tests detect Alzheimer's-related biological signals from a standard blood draw. For healthcare systems already stretched thin on dementia specialists and advanced imaging infrastructure, that difference is significant. A blood draw is universally familiar, requiring far less specialized setup.
The timing is strategically important. Life expectancy across Latin America has risen substantially in recent decades, creating a larger population at risk for age-related cognitive decline. Simultaneously, new Alzheimer's therapies are entering the market that show greater benefit when patients are identified earlier in the disease course. Earlier, more accessible assessment could help more patients qualify for timely intervention.
C2N is clear that its Precivity tests are designed to complement, not replace, physician clinical judgment. They provide one additional layer of biological information to help guide diagnostic decisions. For regions with limited access to specialists, even that incremental information can meaningfully improve care pathways.
There are real caveats. Blood biomarker testing for Alzheimer's is still an evolving field, with questions remaining about specificity, population-level validation, and how results translate into clinical action in resource-limited settings. Expanding test access does not automatically solve shortages of specialists to interpret and act on results. Nonetheless, this partnership represents a meaningful step toward democratizing Alzheimer's assessment, and it reflects a growing recognition that longevity gains are only meaningful if healthcare systems can manage the diseases that accompany longer lives.
Key Findings
- Blood-based Alzheimer's biomarker tests are expanding to 9 Latin American and Caribbean countries via a new diagnostics partnership.
- Precivity tests detect Alzheimer's-linked biological signals from a standard blood draw, reducing need for costly brain imaging.
- Growing aging populations in LATAM face rising dementia burden with limited specialist and imaging infrastructure.
- Earlier Alzheimer's detection is increasingly critical as new therapies show greatest benefit in early disease stages.
- Tests are designed to support, not replace, physician clinical assessment — they add information, not a standalone diagnosis.
Methodology
This is a news report summarizing a commercial partnership announcement, not a peer-reviewed study. The source, Longevity.Technology, is a credible longevity-focused media outlet. Evidence for the Precivity platform's scientific validity rests on C2N's published research, though this article does not cite specific clinical trial data.
Study Limitations
The article is based on a partnership announcement and does not include independent clinical validation data for the Precivity tests in LATAM populations. Questions around test specificity, local regulatory approval, and specialist capacity to act on results are not fully addressed. Readers should consult primary research and regional healthcare guidelines before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.